When Two Worlds Collide – BTG Brings Interventional Oncology And Immunotherapy Together
BTG's range of interventional oncology technologies puts it in an enviable position in R&D initiatives that require a holistic view across cancer and the best-targeted therapies. The UK-listed company will now take this to another level following an agreement with the Society of Interventional Oncology to explore the role of minimally invasive therapies in immuno-oncology.
You may also be interested in...
UK-listed BTG PLC is on a route to a major future in interventional medicine, having built solid foundations in licensing and specialty pharma. CEO Louise Makin describes the deal- and decision-making rationale that has allowed a mid-cap player to set billion-dollar plus ambitions in interventional medicine, based on organic and M&A growth.
The spotlight is on IVDs in the post-COVID phase. Innovators in university spin-outs and the established industry have responded with new technologies, creating a vibrant scene. Regulators and reimbursors must not disrupt the momentum, say BIVDA’s regulatory affairs manager Ashleigh Batchen and chief executive Doris-Ann Williams.
After a runaway 2021 and a strong if bumpy first quarter of 2022, all health care product sectors underwent an investment dip in the second quarter, says Silicon Valley Bank. Healthtech in Europe remained a stand-out performer.